Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 4 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
YNIOS Pharma from La Hulpe, company number BE0783494239, closed financial year 2025 with a result of € -228,903 after tax. For that financial year YNIOS Pharma recorded a gross margin of € -4,809 and equity of € 473,563. Compared with financial year 2024, the result moved from € 342,124 to € -228,903. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 12, 2026.
€ 473,563
▼ 33% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -228,903
▼ still € 342,124 profit in 2024
Profit after tax over the fiscal year.
€ 4,753
▼ 98% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -218,237.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 2,500
▼ 66% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 378
▲ 23% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -133,591 | € -161,833 | € 392,886 | € -4,809 | ▼ € 397,695 |
| Profit after taxes | € -135,009 | € -196,449 | € 342,124 | € -228,903 | ▼ € 571,027 |
| Equity | € 71,991 | € 75,542 | € 702,466 | € 473,563 | ▼ 33% |
| Total debts | € 55,095 | € 143,115 | € 267,824 | € 320,896 | ▲ 20% |
| Cash | € 5,919 | € 50,234 | € 257,192 | € 4,753 | ▼ 98% |
| Retained profit | € -135,009 | € -331,458 | € 10,666 | € -218,237 | ▼ € 228,903 |
| Bank debt | € 0 | € 100,000 | € 0 | € 0 | |
| Balance sheet total | € 127,086 | € 218,657 | € 970,290 | € 794,459 | ▼ 18% |
Key figures of YNIOS Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to YNIOS Pharma?
What happened at YNIOS Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 228,903 (▼ € 571,027 vs 2024). Source: NBB ↗
- Start of the company according to the CBE. KBO
In short
From € 135,009 loss in 2022 to € 228,903 loss in 2025.
Best year ever: 2024, with € 342,124 profit.
Management
Behind YNIOS Pharma are Jean-François PLUCKER and Wescons SRL. Jean-François PLUCKER is also behind STRAME.
Directors
According to the 2025 annual accounts
Director
Establishments
Establishment units
Physical locations of this company
Avenue Wolfers 32
1310 La Hulpe
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
OVH, FR
DNS
OVH DNS
Domain
Domain
yniospharma.com
Registered
2022-02-21
Registrar
OVH, SAS
Expires
2027-02-21
Website info
Features
Security
Network
Details
- Company number
- 0783.494.239
- VAT number
- BE 0783.494.239
- Registered office
- Avenue Wolfers 32, 1310 La Hulpe
- Names & denominations
- YNIOS Pharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 16 March 2022
- Peppol
- Active · Active since 28 Jan 2026
- Contact
- yniospharma.com [email protected]
- Activities · NACE
Vervaardiging van parfums en toiletartikelen
Speur- en ontwikkelingswerk op biotechnologisch gebied
Detailhandel in cosmetica en toiletartikelen